Objective: The severe epilepsies of infancy (SEI) are a devastating group of disorders that pose a major care and economic burden on society; early diagnosis is critical for optimal management. This study sought to determine the incidence and etiologies of SEI, and model the yield and cost-effectiveness of early genetic testing. Methods: A population-based study was undertaken of the incidence, etiologies, and cost-effectiveness of a whole exome sequencing-based gene panel (targeted WES) in infants with SEI born during 2011-2013, identified through electroencephalography (EEG) and neonatal databases. SEI was defined as seizure onset before age 18 months, frequent seizures, epileptiform EEG, and failure of ≥2 antiepileptic drugs. Medical records, investigations, MRIs, and EEGs were analyzed, and genetic testing was performed if no etiology was identified. Economic modeling was performed to determine yield and cost-effectiveness of investigation of infants with unknown etiology at epilepsy onset, incorporating targeted WES at different stages of the diagnostic pathway. Results: Of 114 infants with SEI (incidence = 54/100 000 live births/y), the etiology was determined in 76 (67%): acquired brain injuries (n = 14), focal cortical dysplasias (n = 14), other brain malformations (n = 17), channelopathies (n = 11), chromosomal (n = 9), metabolic (n = 6), and other genetic (n = 5) disorders. Modeling showed that incorporating targeted WES increased diagnostic yield 
| INTRODUCTION
Epilepsy affects >50 million people worldwide. 1 Severe epilepsies of infancy (SEI) are characterized by frequent seizures, epileptiform electroencephalographic (EEG) abnormalities, and antiepileptic drug (AED) resistance. They include epileptic syndromes such as early infantile epileptic encephalopathy, epilepsy of infancy with migrating focal seizures, and infantile spasms (West syndrome). [2] [3] [4] Developmental outcome is often poor, comorbidities frequent, and mortality high due to the effects of seizures and consequences of severe neurological impairment. SEI consume significant diagnostic and therapeutic health care resources. SEI are caused by numerous genetic and acquired disorders, although the etiology often remains unknown. 3, 4 Current diagnostic testing includes imaging, chromosomal, and metabolic testing, typically performed in a tiered or staged fashion (Table 1) , with variable use of genetic testing. 5, 6 The yield of whole exome sequencing (WES), a next generation sequencing (NGS) technology that enables interrogation of large numbers of genes in parallel, in research cohorts of severe epilepsies of childhood varies from 10% to 72%. However, use of WES and other genetic testing in clinical practice is limited by availability, cost, and lack of evidence of cost-effectiveness in population-based settings. 7, 8 Early diagnosis of etiology is critical, as prompt, optimal treatment may improve outcomes. 3, 9, 10 This is already established for surgically remediable epilepsies and will become increasingly important as novel therapies are developed for genetic epilepsies. This population-based study aimed to establish the incidence and etiologies of SEI, and model the diagnostic pediatricians. The advanced, centralized nature of the Victorian health system provides an ideal environment to conduct an epidemiological study, as illustrated by other populationbased studies (eg, www.neuroscience.org.au/australianepilepsy-pregnancy-register, www.auscr.com.au, NEMESIS stroke study).
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The study began in 2013; ascertainment was retrospective for infants presenting during 2011-2012 and prospective for 2013-2015. Infants with potential SEI were identified by review of all EEG reports in children <2 years old in Victoria during 2011-2015 (n = 4505), search of NICU databases for neonates with seizures born during 2011-2013 (n = 379), and regular questioning of pediatric neurologists (Figure 1 ). Medical records of infants with potential SEI were reviewed to determine whether inclusion criteria were met.
| Assessment
All infants meeting SEI inclusion criteria (n = 114) were studied to determine their electroclinical phenotype and underlying etiology. 2 Research genetic testing in infants whose etiology was unknown included: targeted WES (n = 40 infants), molecular inversion probes (MIPs) with panels of 39-65 epilepsy genes (n = 32; Tables S1 and S2) (Table 2A ). The time horizon began at epilepsy onset. In the 7 modeled pathways, each infant with unknown etiology prior to epilepsy onset progressed through the tiers until the first investigation that would have yielded the diagnosis, regardless of whether seizures were ongoing (Model A). Targeted WES was the only NGS technology used in the modeling. The model considered targeted WES to be diagnostic in all infants with single gene disorders with exonic mutations identified using any genetic technology as long as the gene was well covered and analyzed in the targeted WES. In the model, WES was considered negative in only 1 infant with a single gene disorder (whose diagnosis was made on WGS following negative WES).
Infants with brain malformations visible on their initial MRI were considered to have a Tier 1 testing diagnosis, even if their malformation was only recognized after repeat imaging or imaging review (n = 4). The model considered that Tier 3 testing would only be performed in infants with ongoing seizures (in both Models A and B), significant developmental delay, and no clinical suspicion of an occult brain malformation.
The models used the infants' actual diagnoses and a standard cost for each tier of testing (Table 1) . For example, the cost of testing for an infant with a diagnosis made on Tier 1 testing was $3202, and the cost of testing for an infant who had no diagnosis made was $13 899 for Pathway 2 (Table 2A; Costs were calculated using data from the Australian Medicare Benefits Schedule, Royal Children's Hospital Step 4 Step (Tables S3 and S4) . Treatment-related costs were excluded. Costs were converted to U.S. dollars (USD; exchange rate: 1 Australian dollar = $0.745 USD). For infants with a suspected genetic diagnosis at a particular point along the pathway, the costs of targeted testing were added to the total costs (Table S5) , for example SCN1A testing in suspected Dravet syndrome. If targeted WES was performed immediately after the tier at which a diagnosis was suspected, it was considered that the diagnosis would be confirmed on targeted WES rather than targeted gene testing. For Dravet syndrome, we assumed the diagnosis would be suspected after Tier 1 testing. The cost for Pathway 2 would then be $3854 (Tier 1 $3202? SCN1A sequencing $652) and the cost for Pathway 5 $4841 (Tier 1 $3202?targeted WES $1639). The costs of genetic testing were not included where infants had a clearcut etiology (eg, tuberous sclerosis diagnosed on MRI). The model considered that infants with or without an affected sibling would progress through the pathway in the same manner (Supporting Information; Health Economic Evaluation-Affected Siblings section).
For each pathway, the number of diagnoses, total cost, cost per diagnosis, and cost per patient were calculated. Incremental cost-effectiveness ratio (ICER), defined as the cost required to make 1 additional diagnosis, was calculated for each pathway relative to Pathway 1 without targeted WES. The formula used was (total cost Pathway X À total cost Pathway 1) / (number of diagnoses in Pathway X À number of diagnoses in Pathway 1). Willingness to pay was defined as the maximum amount that a funder (eg, hospital/insurance company) would be willing to pay to achieve an additional diagnosis.
Sensitivity analyses were performed on Model A (for Pathways 1, 2, 5, and 7), varying the cost of WES (AE20%), the diagnostic yield of targeted WES (AE4 diagnoses), and the diagnostic yield of the first MRI brain scan (AE4 diagnoses) to determine the impact of variability in cost and yield of these investigations on the ICER relative to Pathway 1. An additional sensitivity analysis was performed (Model B), using the assumption that infants would only continue beyond Step 1 of the pathway if seizures were ongoing (Step 2 performed if seizures were ongoing 1 month after presentation, Step 3 if ongoing at 3 months, Steps 4 and 5 if ongoing at 6 months).
The CHEERS guidelines for reporting economic evaluations were followed (https://www.ispor.org/Health-Econo mic-Evaluation-Publication-CHEERS-Guidelines.asp).
| Study approvals
The study was approved by the human research and ethics committees of RCH, Monash Children's Hospital, Royal Women's Hospital, Mercy Hospital for Women, Austin Health, and Geelong Hospital. Written informed consent was obtained for research clinical assessments and genetic testing.
| RESULTS

| Incidence
One hundred fourteen infants with SEI were born in Victoria during 2011-2013. All were identified through EEG laboratories, 11 from NICU databases (Figure 1) , and 43 from neurologist referrals. One hundred seven (94%) infants were identified multiple times, 47 from >1 source and 60 from multiple EEGs. During 2011-2013, there were 222 818 live births in Victoria, yielding an incidence of SEI, adjusted for population migration (Supporting Information; Incidence Adjusted for Population Migration section), of 54 of 100 000 live births/y (95% confidence interval = 45-65/100 000). Infantile spasms occurred in 74 infants, with an adjusted incidence of 35 of 100 000 live births/y (95% confidence interval = 28-44/100 000).
| Etiology
Etiology was identified in 76 (67%) infants (Table 3) . Fourteen (12%) had an acquired brain injury, 62 (54%) had genetic or presumed genetic etiologies, and 38 (33%) had unknown etiologies. Brain malformations were identified in 31 (27%), including focal cortical dysplasia (FCD) in 14 (12%). Six (5%) infants had metabolic disorders, 9 (8%) had chromosomal abnormalities, and 16 (14%) had single gene disorders (excluding genes for malformation and metabolic disorders), including 11 (10%) with channelopathies.
The etiology was known prior to epilepsy onset in 28 (25%) infants, including all 14 with acquired etiologies. Thirty-seven of 86 (32%) infants with unknown etiology prior to epilepsy onset had a diagnosis subsequently made on clinical evaluation (including nonresearch genetic testing in 5 and research imaging review in 4). Forty-four of 49 infants with unknown etiology consented to research genetic testing, the etiology being identified in 11 (25% ; Table S6 ).
Among infants with unknown etiology prior to epilepsy onset, the highest diagnostic yield investigations were (nonchromosomal) genetic testing (16/49 [32%] ) and brain MRI (26/85 [31%] ). The genetic tests yielding a diagnosis were single gene testing (n = 5), 4-gene panel (n = 1), MIPs (n = 3), targeted WES (n = 6) and WGS (n = 1; Table S7 ). Nine infants had a variant of unknown significance (VUS) identified on targeted WES. Chromosomal microarray was diagnostic in 4 of 74 (5%) infants.
Genetic diagnoses informed reproductive counseling in all infants, and led to management change in 1 (SCN2A mutation with sodium channel-blocking AEDs used 15 ) and informed prognostic counseling in most. A significant recurrence risk was identified in 5 families: 2 with somatic mosaicism in an unaffected parent (submitted), 1 with 2 affected children and presumed parental mosaicism, and 2 with heterozygous carrier parents for a recessive disorder.
| Economic modeling
Using Model A ( 
Other: Aicardi-Gouti eres syndrome, SMC1A mutation, Sotos syndrome, SYNGAP1 mutation, TBC1D24 mutation diagnosis ($9904 USD) were considerably reduced in this pathway compared with Pathway 1. Pathways 6 and 7, in which targeted WES was used earliest in the diagnostic pathway (after Tier 1 investigations) with Tier 3 AE 2 investigations omitted were the most cost-effective relative to Pathway 1. They produced an incremental cost-effectiveness ratio that was "dominant," that is, was cheaper and more effective than Pathway 1. Pathways 3, 4, and 5 had incremental ratios of $1775-$3650 USD per additional diagnosis achieved. These could be considered cost-effective if the willingness to pay was at least $3650 USD per additional diagnosis made. Pathway 2, in which targeted WES was placed last in the diagnostic pathway, was the least cost-effective, with an incremental ratio of $8559 USD per additional diagnosis achieved relative to Pathway 1.
We varied the cost of targeted WES and the yield of targeted WES and MRI in Model A and obtained similar results for most scenarios (Figure 3 ). The only scenarios in which the pattern of results differed from the base case analysis (Model A) were in Pathway 5, in which WES became dominant when the diagnostic yield was increased (4 additional diagnoses, diagnostic rate = 33%) or the cost reduced (by 20%). For Pathways 2 and 5, the sensitivity analyses showed that economic modeling was more sensitive to (varied more with) assumptions about WES yield than WES cost Table S8 ).
| DISCUSSION
Understanding the epidemiology and etiologies of SEI is essential for optimization of diagnostic strategies. The approach taken in this study is pertinent to many human disorders with heterogeneous etiologies, providing a basis for estimating the burden of disease and potential avenues for precision medicine. We found that SEI have an incidence of 1 in 2000 live births, greater than Duchenne muscular dystrophy (1/4000) and neurofibromatosis type 1 (1/ 2700). 16, 17 The incidence of infantile spasms in this study (approximately 1/3000) was similar to previous reports, providing some validation of the study methodology. 18 The health burden of SEI accounts for a significant proportion of pediatric inpatient costs, with huge psychosocial and economic impacts on families and society. 19, 20 We identified the etiology in two-thirds of infants with SEI, with research genetic testing and expert review of MRI. This high yield carries critical prognostic and genetic counseling implications for most patients, and therapeutic F I G U R E 2 Yield of modeled diagnostic pathway (A) without whole exome sequencing (Pathway 1) and (B) with early whole exome sequencing (Pathway 5). These models assumed that infants suspected clinically to have occult brain malformations did not undergo Tier 3 testing. CMA, chromosomal microarray; MRI, magnetic resonance imaging; UMS, urine metabolic screen; WES, targeted whole exome sequencing implications in some. Acquired causes such as hypoxicischemic encephalopathy accounted for only 12% of infants; however, perinatal causes will be more common in developing countries. 21 A key finding with management implications was that brain malformations comprised the most common etiological group (27%). FCD predominated (12% patients), and represents a critical group for early diagnosis, as surgery may control seizures, potentially enabling developmental acceleration. 10 MRI sequences that increase sensitivity to identify FCD (eg, double inversion recovery sequences), 22 together with expert review, and repeat brain imaging later in infancy, facilitate detection of occult FCD; advances in imaging promise to further improve detection. Single gene disorders (excluding those associated with malformations or metabolic disorders) were identified in 14% of cases, including 32% of infants in whom MRI, metabolic, and chromosomal testing were nondiagnostic, similar to gene panel yield in non-population-based cohorts. 23, 24 We may have underestimated the yield of targeted WES, as the parents of 5 infants declined genetic testing. Given the genetic heterogeneity of SEI, our numbers were too small to determine which genes are most common; however, ion channel gene mutations were found in 11 of 16 cases. One-third of infants remain without a diagnosis, most despite targeted WES. Our economic modeling established at a population level that targeted WES increases diagnostic yield. Diagnostic costs are lower when targeted WES is performed early in the diagnostic evaluation and are comparable to the cost of investigation without targeted WES. Early targeted WES becomes overwhelmingly cost-effective when the low yield Tier 2 and 3 metabolic testing is also removed from the diagnostic pathway.
Our model likely underestimates the diagnostic yield and cost-effectiveness of WES, as we did not interrogate genes other than those in our panel. Conversely, we did not include the cost of investigating VUS. We also did not F I G U R E 3 Economic evaluation 1-way sensitivity analyses for Model A (base case analysis) comparing Pathways 2, 5, and 7 with Pathway 1. ICER, incremental cost-effectiveness ratio; USD, U.S. dollars. *Yield of targeted whole exome sequencing (WES) and magnetic resonance imaging (MRI) was increased or decreased by 4 diagnoses from that of the base case analysis.^Model B; infants continued through the diagnostic pathway until an etiology was identified only if seizures were ongoing. "Dominates" refers to an economic evaluation result where the intervention/pathway is cheaper and more effective (ie, greater yield) than the comparison consider indirect cost benefits of making an etiologic diagnosis, an important area for future research. The potential benefits of early diagnosis, including optimizing treatments, recognition of comorbidities, and accurate reproductive counseling, will improve health and economic outcomes. 25 Implementation of WES into clinical practice is currently a major focus in many areas of medicine. WES has improved rates of etiologic diagnosis in conditions with high genetic heterogeneity and phenotypic overlap, such as epilepsy. However, optimal use of WES depends not only on diagnostic yield, but also on cost-effectiveness relative to either not using WES or using it late in the diagnostic pathway. This is the first economic study of the utility of WES in epilepsy, with few reported for other conditions. 26 WES will reduce use of nongenetic, low-yield, and often repeated or invasive investigations. Gene panel analysis (non-WES-based) is an alternative clinical NGS technology. The utility of targeted WES over gene panels was not compared. Although there is considerable variability, gene panel analyses are typically cheaper and more rapidly analyzed. A major advantage of targeted WES is that, when negative, data can be reanalyzed for new genes as they emerge, or exome-wide analysis can be performed. Thus, additional sequencing costs are not incurred (apart from scientists' time for data reanalysis). In our modeling, 18 diagnoses were made on WES. Two commercially available epilepsy gene panels include the causative genes in 14 of 18 (GeneDx, www.genedx.com) and 16 of 18 (Ambry Genetics, www.ambrygen.com) patients. Our sensitivity analysis showed that early targeted WES and limited metabolic testing remained cost-effective even when the yield of WES was reduced to 14 instead of 18 diagnoses. Given this, gene panel analysis would also likely be cost-effective relative to investigation without another NGS technology, although the subsequent need for WES when the panel is negative would add significantly to the total cost. In the future, newer molecular techniques such as WGS will likely supersede current technologies, although their utility in SEI is not yet known.
In SEI, there is an argument for limiting second-and third-tier metabolic testing at the group level, given its low yield, invasiveness, and high cost. Metabolic disorders are genetically determined, such that WES may obviate the need for complex biochemical testing (with the exception of some mitochondrial disorders, as WES does not detect mutations in the mitochondrial genome). However, in clinically suspected treatable metabolic conditions, the turnaround time for metabolic testing may be faster, and therefore warranted until genomic testing is more rapid. Although the simulated diagnostic pathway in which second-and third-tier metabolic testing was removed yielded 2 fewer diagnoses, these diagnoses were strongly suspected on clinical grounds and were diagnosed with targeted metabolic testing. Targeted testing should be performed in infants in whom a metabolic diagnosis is strongly suspected and in subgroups with higher likelihood of treatable metabolic conditions, such as neonates and parental consanguinity. 6 Although not modeled here, the yield of firsttier metabolic testing and chromosomal microarray probably warrants their continued use. 31, 32 Our cohort is population-based, but relatively small. Thus, an important consideration is whether our findings are generalizable to similar (high income, low perinatal morbidity) populations. Given the heterogeneity of SEI, there will undoubtedly be differences in etiologies between similar populations. However, it is likely that the proportion of patients in each etiologic group (malformative vs metabolic vs genetic) will vary considerably less. Supporting this assumption are Canadian and U.S. studies of infantile epilepsies showing similarly low rates of metabolic disorders to our study. 31, 33 Thus, there is likely to be less difference between the yield of each diagnostic test than actual etiologies. Our sensitivity analyses, in which the yield of MRI or WES was increased or reduced as a proxy for variability in the proportion of patients with malformative and single gene disorders, showed that early WES is cost-effective across the range of diagnostic yields modeled. The cost of WES and other diagnostic investigations may vary between countries. For example, the cost of singleton WES reported in health economic studies from the United States is $1060-2471 USD. 34 Although we did not specifically model the costs of all diagnostic investigations in other countries, our sensitivity analysis showed that early targeted WES is cost-effective across the range of WES prices modeled ($1639 USD AE 20%), which is within the aforementioned range of U.S. prices. There may be different challenges in obtaining funding for WES in all health care settings, be they "public" (government pays) or "private" (insurance company or patient pays). However, where the funder is also responsible for the costs of other diagnostic investigations, the cost-savings achieved through preventing costly metabolic and reimaging investigations is likely to provide sufficient incentive for performing early targeted WES. Early targeted WES in SEI where initial MRI, chromosomal microarray, and Tier 1 metabolic investigations are negative is both clinically effective and costeffective. Not performing targeted WES, and performing it as a final investigation after exhaustive metabolic and specific genetic testing, are suboptimal diagnostic approaches. Early diagnosis of the etiology of a child's severe epilepsy may carry time-critical genetic counseling and management implications.
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